These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 37339840)

  • 21. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 Jul; 12(7):e060425. PubMed ID: 35777878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis.
    Krug A; Stevenson J; Høeg TB
    Eur J Clin Invest; 2022 May; 52(5):e13759. PubMed ID: 35156705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
    Chen C; Chen C; Cao L; Fang J; Xiao J
    Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
    Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States.
    Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A
    Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy.
    Corrao G; Franchi M; Cereda D; Bortolan F; Leoni O; Vignati E; Pavesi G; Gori A
    BMC Infect Dis; 2022 Nov; 22(1):844. PubMed ID: 36371165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myocarditis and pericarditis following mRNA COVID-19 vaccination. Expert opinion of the Italian Society of Cardiology].
    Sinagra G; Porcari A; Merlo M; Barillà F; Basso C; Ciccone MM; Curcio A; Mancone M; Mercuro G; Muscoli S; Nodari S; Pedrinelli R; Spaccarotella C; Filardi PP; Indolfi C
    G Ital Cardiol (Rome); 2021 Nov; 22(11):894-899. PubMed ID: 34709228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination.
    Piché-Renaud PP; Morris SK; Top KA
    Br J Clin Pharmacol; 2023 Mar; 89(3):967-981. PubMed ID: 36480113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
    Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
    JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital.
    Elizalde MU; Eguinoa FJG; de Las Huertas AGL; Jiménez-González M; Ramírez E
    Biomed Pharmacother; 2024 Feb; 171():116181. PubMed ID: 38262150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19, Myocarditis and Pericarditis.
    Fairweather D; Beetler DJ; Di Florio DN; Musigk N; Heidecker B; Cooper LT
    Circ Res; 2023 May; 132(10):1302-1319. PubMed ID: 37167363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: A systematic review.
    Fatima M; Khan MHA; Ali MS; Osama M; Cheema HA; Ahmed A; Nisar A; Murad MW; Farooq H; Aemaz Ur Rehman M; Swed S; Akbar UA
    Clin Cardiol; 2023 Mar; 46(3):243-259. PubMed ID: 36594165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach.
    Anastassopoulou C; Hatziantoniou S; Vlachopoulos C; Spanakis N; Tsioufis C; Tsakris A; Lazaros G
    Int J Cardiol; 2022 Jul; 358():136-139. PubMed ID: 35436559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the temporal and cause-effect relationship between myocarditis and mRNA COVID-19 vaccines. A retrospective observational study.
    Bianchi FP; Rizzi D; Daleno A; Stefanizzi P; Migliore G; Tafuri S
    Int J Infect Dis; 2024 Apr; 141():106960. PubMed ID: 38365084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks of Myocarditis and Pericarditis Following Vaccination with SARS-CoV-2 mRNA Vaccines in Japan: An Analysis of Spontaneous Reports of Suspected Adverse Events.
    Kobayashi H; Fukuda S; Matsukawa R; Asakura Y; Kanno Y; Hatta T; Saito Y; Shimizu Y; Kawarasaki S; Kihara M; Kinoshita N; Umeda H; Noda T; Imamura T; Nishioka Y; Yamaguchi T; Hayashi S; Iguchi T
    Ther Innov Regul Sci; 2023 Mar; 57(2):329-342. PubMed ID: 36310329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute Myocarditis and Pericarditis After mRNA COVID-19 Vaccinations-A Single-Centre Retrospective Analysis.
    Wassif M; Lo P; Satouris P; Swan L; Tardo D; Kovacic JC; Muller D; Muthiah K; Kotlyar E; Bart NK
    Heart Lung Circ; 2023 Apr; 32(4):467-479. PubMed ID: 36841638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.
    Le Vu S; Bertrand M; Jabagi MJ; Botton J; Drouin J; Baricault B; Weill A; Dray-Spira R; Zureik M
    Nat Commun; 2022 Jun; 13(1):3633. PubMed ID: 35752614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Fix J; Christopher Mast T; Smith K; Baker N
    Vaccine; 2024 Apr; 42(9):2161-2165. PubMed ID: 38494410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.